These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 39410752)

  • 21. Polyethylene glycol-based linkers as hydrophilicity reservoir for antibody-drug conjugates.
    Tedeschini T; Campara B; Grigoletto A; Bellini M; Salvalaio M; Matsuno Y; Suzuki A; Yoshioka H; Pasut G
    J Control Release; 2021 Sep; 337():431-447. PubMed ID: 34329685
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Payload Hydrophobicity on the Stability of Antibody-Drug Conjugates.
    Buecheler JW; Winzer M; Tonillo J; Weber C; Gieseler H
    Mol Pharm; 2018 Jul; 15(7):2656-2664. PubMed ID: 29809017
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Drug Conjugation and Loading on Target Antigen Binding and Cytotoxicity in Cysteine Antibody-Drug Conjugates.
    Nadkarni DV; Lee J; Jiang Q; Patel V; Sriskanda V; Dutta K; Meyer DM
    Mol Pharm; 2021 Mar; 18(3):889-897. PubMed ID: 33470823
    [TBL] [Abstract][Full Text] [Related]  

  • 24. "Negative" Impact: The Role of Payload Charge in the Physicochemical Stability of Auristatin Antibody-Drug Conjugates.
    Johann F; Wöll S; Gieseler H
    J Pharm Sci; 2024 Aug; 113(8):2433-2442. PubMed ID: 38679233
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of Novel Quaternary Ammonium Linkers for Antibody-Drug Conjugates.
    Burke PJ; Hamilton JZ; Pires TA; Setter JR; Hunter JH; Cochran JH; Waight AB; Gordon KA; Toki BE; Emmerton KK; Zeng W; Stone IJ; Senter PD; Lyon RP; Jeffrey SC
    Mol Cancer Ther; 2016 May; 15(5):938-45. PubMed ID: 26944920
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aldehyde tag coupled with HIPS chemistry enables the production of ADCs conjugated site-specifically to different antibody regions with distinct in vivo efficacy and PK outcomes.
    Drake PM; Albers AE; Baker J; Banas S; Barfield RM; Bhat AS; de Hart GW; Garofalo AW; Holder P; Jones LC; Kudirka R; McFarland J; Zmolek W; Rabuka D
    Bioconjug Chem; 2014 Jul; 25(7):1331-41. PubMed ID: 24924618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of cathepsin B-sensitive triggers and hydrophilic linkers on in vitro efficacy of novel site-specific antibody-drug conjugates.
    Bryden F; Martin C; Letast S; Lles E; Viéitez-Villemin I; Rousseau A; Colas C; Brachet-Botineau M; Allard-Vannier E; Larbouret C; Viaud-Massuard MC; Joubert N
    Org Biomol Chem; 2018 Mar; 16(11):1882-1889. PubMed ID: 29473076
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Generation and Characterization of Iduronidase-Cleavable ADCs.
    Jäger S; Könning D; Rasche N; Hart F; Sensbach J; Krug C; Raab-Westphal S; Richter K; Unverzagt C; Hecht S; Anderl J; Schröter C
    Bioconjug Chem; 2023 Dec; 34(12):2221-2233. PubMed ID: 38054705
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potent antitumor activity of anti-HER2 antibody-topoisomerase I inhibitor conjugate based on self-immolative dendritic dimeric-linker.
    Liubomirski Y; Tiram G; Scomparin A; Gnaim S; Das S; Gholap S; Ge L; Yeini E; Shelef O; Zauberman A; Berger N; Kalimi D; Toister-Achituv M; Schröter C; Dickgiesser S; Tonillo J; Shan M; Deutsch C; Sweeney-Lasch S; Shabat D; Satchi-Fainaro R
    J Control Release; 2024 Mar; 367():148-157. PubMed ID: 38228272
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Linker Architectures as Steric Auxiliaries for Altering Enzyme-Mediated Payload Release from Bioconjugates.
    Giese M; Davis PD; Woodman RH; Hermanson G; Pokora A; Vermillion M
    Bioconjug Chem; 2021 Oct; 32(10):2257-2267. PubMed ID: 34587447
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Carfilzomib Is Not an Appropriate Payload of Antibody-Drug Conjugates Due to Rapid Inactivation by Lysosomal Enzymes.
    Ma Y; Dela Cruz-Chuh J; Khojasteh SC; Dragovich PS; Pillow TH; Zhang D
    Drug Metab Dispos; 2019 Aug; 47(8):884-889. PubMed ID: 31072822
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An Enzymatically Cleavable Tripeptide Linker for Maximizing the Therapeutic Index of Antibody-Drug Conjugates.
    Ha SYY; Anami Y; Yamazaki CM; Xiong W; Haase CM; Olson SD; Lee J; Ueno NT; Zhang N; An Z; Tsuchikama K
    Mol Cancer Ther; 2022 Sep; 21(9):1449-1461. PubMed ID: 35793453
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
    Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
    Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Linkers Having a Crucial Role in Antibody-Drug Conjugates.
    Lu J; Jiang F; Lu A; Zhang G
    Int J Mol Sci; 2016 Apr; 17(4):561. PubMed ID: 27089329
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody-Drug Conjugates.
    Schmitt S; Machui P; Mai I; Herterich S; Wunder S; Cyprys P; Gerlach M; Ochtrop P; Hackenberger CPR; Schumacher D; Helma J; Vogl AM; Kasper MA
    Mol Cancer Ther; 2024 Feb; 23(2):199-211. PubMed ID: 37828728
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enzymatic conjugation using branched linkers for constructing homogeneous antibody-drug conjugates with high potency.
    Anami Y; Xiong W; Gui X; Deng M; Zhang CC; Zhang N; An Z; Tsuchikama K
    Org Biomol Chem; 2017 Jul; 15(26):5635-5642. PubMed ID: 28649690
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, Synthesis, and in vitro Evaluation of Multivalent Drug Linkers for High-Drug-Load Antibody-Drug Conjugates.
    Chen B; Gianolio DA; Stefano JE; Manning CM; Gregory RC; Busch MM; Brondyk WH; Miller RJ; Dhal PK
    ChemMedChem; 2018 Apr; 13(8):790-794. PubMed ID: 29517131
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index.
    Lyon RP; Bovee TD; Doronina SO; Burke PJ; Hunter JH; Neff-LaFord HD; Jonas M; Anderson ME; Setter JR; Senter PD
    Nat Biotechnol; 2015 Jul; 33(7):733-5. PubMed ID: 26076429
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determination of drug-to-antibody ratio of antibody-drug conjugate in biological samples using microflow-liquid chromatography/high-resolution mass spectrometry.
    Inoue K; Mochizuki T; Kasamori N; Komori T
    Bioanalysis; 2022 Dec; 14(24):1533-1545. PubMed ID: 36825963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Contribution of linker stability to the activities of anticancer immunoconjugates.
    Alley SC; Benjamin DR; Jeffrey SC; Okeley NM; Meyer DL; Sanderson RJ; Senter PD
    Bioconjug Chem; 2008 Mar; 19(3):759-65. PubMed ID: 18314937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.